Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.
about
Nucleic Acid sensors and type I interferon production in systemic lupus erythematosusInterferon-induced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into dendritic cell-like cellsPolymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosusInterpreting interest in interferon-alphaSystemic lupus erythematosus and the type I interferon systemCytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus ErythematosusInflammatory cytokines in systemic lupus erythematosusToll-like receptors in systemic lupus erythematosus: potential targets for therapeutic interventionRole of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunityEmerging therapies for systemic lupus erythematosus--focus on targeting interferon-alphaInterferon alpha-induced lupus: proof of principleHigh serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosusTwist mediates suppression of inflammation by type I IFNs and AxlInterferon alpha on NZM2328.Lc1R27: enhancing autoimmunity and immune complex-mediated glomerulonephritis without end stage renal failureGenetic regulation of serum cytokines in systemic lupus erythematosusThe role of the T cell in autoimmune inflammation.Systemic sclerosis and lupus: points in an interferon-mediated continuum.Interferon alpha in systemic lupus erythematosusDeficiency of the type I interferon receptor protects mice from experimental lupus.Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus.Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naïve T cells into cytokine-producing mature T cells.A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus.Deficiency in either 4E-BP1 or 4E-BP2 augments innate antiviral immune responsesThe interplay of dendritic cell subsets in systemic lupus erythematosus.Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane)Adalimumab-induced lupus serositis.Type I interferon correlates with serological and clinical manifestations of SLEInterferon alpha as a primary pathogenic factor in human lupusType I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis.Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor.Induction of clinical autoimmune disease by therapeutic interferon-alpha.Potential mechanisms of interferon-alpha induced autoimmunity.Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-α and serologic autoimmunity in lupus patients.Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab.Significance of the cytokine interferon gamma in clinical dermatology.Severe inflammatory arthritis and lymphadenopathy in the absence of TNF.Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening.Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.Directing autoimmunity to nucleoprotein particles: the impact of dendritic cells and interferon alpha in lupusType-I interferon receptor deficiency reduces lupus-like disease in NZB mice.
P2860
Q21131202-3C220769-8530-4C79-8EBF-233E05EAA461Q24323367-F05DC5BA-5C81-4B7A-972F-3946D2927CBFQ24530690-36843733-ACD5-4111-BF4E-3EF1591FBA61Q24797820-F476FA54-EB61-43FF-9B46-0A721B988FFDQ24804235-B16C819D-83D6-4351-8342-1D901F17BEE5Q26782454-F1BA24EA-81E3-4102-8627-F7B603409355Q26823647-9C598813-B24F-4842-B66B-93A5A35ED344Q26865485-E5362142-AF40-4F17-8C59-0CEECD368A95Q28246851-54069661-863C-4F09-8BC3-A02894D7A155Q28265144-0754437C-5CAE-47E2-935D-DEEC4932B040Q28282720-05EF9541-9D20-4745-8A44-6C1D050C16FEQ28307075-0B13BC05-04CA-43D9-B4B5-522804CEAD3BQ28509359-BA9E5AA3-D8C8-4B52-9DD8-B87BC742C5E5Q30410652-2C7A076D-0C81-4CA6-AA17-47DFFB4AA684Q33682879-2DF3F880-4611-4CE9-ADBC-59A1368FF72DQ33709343-DBA3AC92-5EA6-4195-85AF-EE6FB8959304Q33889629-E09BD578-5F42-41F8-9815-6429CAEB3FCDQ33961179-E17A0EA8-FCF0-4BAB-904E-25DBAD8BDA71Q34016334-58DA70B0-B28B-4D72-ABA3-35F8979F0AD0Q34027485-343890DE-C2D6-45B3-B8BF-9B563382ED06Q34168242-E5F48563-DD95-4063-BE34-A756F132F544Q34465566-92EE1E8A-7AD0-4795-BB4B-17A5DB7DE9F2Q34756913-4FE38C12-95AB-4B43-9120-8DCBE6BBB179Q34842390-CD18939F-CD0E-4ADC-B21A-B6F6F0D2C144Q35088161-EABA28DA-4B06-4D2B-A303-339295C0D704Q35203953-26D2FAA4-6F1C-41B6-B62A-8D30234423D6Q35555038-B4E4E33D-50DF-41DC-BE8C-3D82CF406352Q35603587-D735AC59-F6F2-4141-8AF1-9521B72B5E6DQ35675517-6A19C9A5-8B73-454B-BB4D-8579B6527A1CQ35675526-1497B7E4-CFFD-4602-BC76-B015D5D4EE28Q35675529-8668660E-A464-4775-9210-6296AB460873Q35675531-9BFDF0DB-3C53-43D1-BC1E-FEDC16EB081BQ35832527-E5A03513-E511-47B4-A88B-1CEBD8866DE9Q35852535-AECE2635-50FD-47F8-87EB-5B5B056AF965Q35953776-7A1BEFE4-FF13-4746-BE54-3B96BA36684FQ36028645-963BE8ED-FEC2-4DE2-B05B-E86A8E890294Q36276815-B3139247-168A-4001-9F6D-F4F410C71BF3Q36360719-7FC3FA74-13C7-43BB-9A88-D1868B256892Q36370588-49BBB07A-2F6E-4F68-9BE1-5FBBF144E2F8Q36370602-442249D9-E6A9-4BC8-9C3F-486B8E490F74
P2860
Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Current evidence for the induc ...... estations by cytokine therapy.
@ast
Current evidence for the induc ...... estations by cytokine therapy.
@en
type
label
Current evidence for the induc ...... estations by cytokine therapy.
@ast
Current evidence for the induc ...... estations by cytokine therapy.
@en
prefLabel
Current evidence for the induc ...... estations by cytokine therapy.
@ast
Current evidence for the induc ...... estations by cytokine therapy.
@en
P2860
P1476
Current evidence for the induc ...... estations by cytokine therapy.
@en
P2093
P2860
P304
P356
10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E
P577
2000-07-01T00:00:00Z